Mubadala Bio Opens High-Potency Drug Facility, Launches New Oncology Medicines in UAE

Mubadala Bio has strengthened the UAE’s pharmaceutical manufacturing capabilities with the opening of a new high-potency drug facility in Abu Dhabi, alongside the launch of a portfolio of advanced oncology medicines. The development marks a significant step toward improving national drug security, ensuring continuity of supply, and enhancing patient access to critical cancer therapies.

The new facility, located at Bioventure Healthcare, a subsidiary of Mubadala Bio, is designed to manufacture high-potency medicines such as oncology and hormone therapies. Built in line with international safety and regulatory standards, the site enables the local production of complex treatments that have traditionally been imported, helping to reduce dependency on overseas supply chains.

Coinciding with the facility’s launch, Mubadala Bio introduced three essential cancer treatments to the UAE market, some of which are being produced locally for the first time as branded generic medicines. These include Lenalidomide, used in the treatment of multiple myeloma; Pomalidomide, also for multiple myeloma and now locally manufactured for the first time in the UAE; and Sunitinib, a targeted therapy for certain advanced and progressive cancers.

The company stated that the new manufacturing capability and product launches are intended to enhance national drug security, improve access to highly needed oncology therapies, and help reduce treatment costs for patients across the country.

Dr Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, said the locally produced medicines add to the company’s expanding pharmaceutical portfolio and support the growth of a more advanced life sciences ecosystem in the UAE.

Dr Essam Mohamed, Chief Executive Officer of Mubadala Bio, highlighted that the investment reflects a long-term commitment to building local manufacturing capabilities, ensuring consistent and reliable access to essential treatments for patients.

Hamad Husein Almarzooqi, Deputy Chief Executive Officer of Mubadala Bio, noted that the high-potency facility significantly expands the company’s ability to address priority healthcare needs by producing complex and high-demand therapies within the UAE. 

The initiative forms part of Mubadala Bio’s broader strategy to strengthen the country’s pharmaceutical manufacturing base, reduce reliance on imports, and position the UAE as a regional hub for advanced life sciences and healthcare innovation.